Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru



ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Лечебное дело
2020 / N 2

Раннее назначение комбинированной сахароснижающей терапии при сахарном диабете 2-го типа: преимущества и недостатки
Т.Б. Моргунова, В.В. Фадеев

Список литературы

1. Министерство здравоохранения РФ; Российская ассоциация эндокринологов; Национальный исследовательский центр эндокринологии. Клинические рекомендации. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. Дедова И.И., Шестаковой М.В., Майорова А.Ю. 9-й выпуск (дополненный). – М.; 2019. 216 с.
2. American Diabetes Association. Standards of medical care in diabetes – 2020. Diabetes Care 2020 Jan;43(Suppl 1).
3. Khunti K, Wolden ML, Thorsted BL, Andersen M, Davies MJ. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care 2013 Nov;36(11):3411-7.
4. Phung OJ, Sobieraj DM, Engel SS, Rajpathak SN. Early combination therapy for the treatment of type 2 diabetes mellitus: systematic review and meta-analysis. Diabetes, Obesity and Metabolism 2014 May;16(5):410-7.
5. Matthews DR, Paldánius PM, Proot P, Chiang Y, Stumvoll M, Del Prato S; VERIFY study group. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. The Lancet 2019 Oct;394(10208):1519-29.
6. Cerf ME. Beta cell dysfunction and insulin resistance. Frontiers in Endocrinology (Lausanne) 2013 Mar;4:37.
7. Takeda Y, Fujita Y, Honjo J, Yanagimachi T, Sakagami H, Takiyama Y, Makino Y, Abiko A, Kieffer TJ, Haneda M. Reduction of both beta cell death and alpha cell proliferation by dipeptidyl peptidase-4 inhibition in a streptozotocin-induced model of diabetes in mice. Diabetologia 2012 Feb;55(2):404-12.
8. Duttaroy A, Voelker F, Merriam K, Zhang X, Ren X, Subramanian K, Hughes TE, Burkey BF. The DPP-4 inhibitor vildagliptin increases pancreatic beta cell mass in neonatal rats. European Journal of Pharmacology 2011 Jan;650(2-3):703-7.
9. Del Prato S, Camisasca R, Wilson C, Fleck P. Durability of the efficacy and safety of alogliptin compared to glipizide in type 2 diabetes mellitus: a 2-year study. Diabetes, Obesity and Metabolism 2014 Dec;16(12):1239-46.
10. DeFronzo RA, Fleck PR, Wilson CA, Mekki Q; Alogliptin Study 010 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care 2008 Dec;31(12):2315-7.
11. Pratley RE, McCall T, Fleck PR, Wilson CA, Mekki Q. Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies. Journal of the American Geriatrics Society 2009 Nov;57(11):2011-9.
12. Nauck MA, Ellis GC, Fleck PR, Wilson CA, Mekki Q; Alogliptin Study 008 Group. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. International Journal of Clinical Practice 2009 Jan;63(1):46-55.
13. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). The Lancet 1998 Sep;352(9131):837-53.
14. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). The Lancet 1998 Sep;352(9131):854-65.

References

1. Ministry of Healthcare of the Russian Federation; Russian Association of Endocrinologists; National Medical Research Center for Endocrinology. Clinical recommendations. Standards of specialized diabetes care. Dedov II, Shestakova MV, Mayorov AYu, editors. 9th ed. (revised). Moscow, 2019. 216 p. (In Russian).
2. American Diabetes Association. Standards of medical care in diabetes – 2020. Diabetes Care 2020 Jan;43(Suppl 1).
3. Khunti K, Wolden ML, Thorsted BL, Andersen M, Davies MJ. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care 2013 Nov;36(11):3411-7.
4. Phung OJ, Sobieraj DM, Engel SS, Rajpathak SN. Early combination therapy for the treatment of type 2 diabetes mellitus: systematic review and meta-analysis. Diabetes, Obesity and Metabolism 2014 May;16(5):410-7.
5. Matthews DR, Paldánius PM, Proot P, Chiang Y, Stumvoll M, Del Prato S; VERIFY study group. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. The Lancet 2019 Oct;394(10208):1519-29.
6. Cerf ME. Beta cell dysfunction and insulin resistance. Frontiers in Endocrinology (Lausanne) 2013 Mar;4:37.
7. Takeda Y, Fujita Y, Honjo J, Yanagimachi T, Sakagami H, Takiyama Y, Makino Y, Abiko A, Kieffer TJ, Haneda M. Reduction of both beta cell death and alpha cell proliferation by dipeptidyl peptidase-4 inhibition in a streptozotocin-induced model of diabetes in mice. Diabetologia 2012 Feb;55(2):404-12.
8. Duttaroy A, Voelker F, Merriam K, Zhang X, Ren X, Subramanian K, Hughes TE, Burkey BF. The DPP-4 inhibitor vildagliptin increases pancreatic beta cell mass in neonatal rats. European Journal of Pharmacology 2011 Jan;650(2-3):703-7.
9. Del Prato S, Camisasca R, Wilson C, Fleck P. Durability of the efficacy and safety of alogliptin compared to glipizide in type 2 diabetes mellitus: a 2-year study. Diabetes, Obesity and Metabolism 2014 Dec;16(12):1239-46.
10. DeFronzo RA, Fleck PR, Wilson CA, Mekki Q; Alogliptin Study 010 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care 2008 Dec;31(12):2315-7.
11. Pratley RE, McCall T, Fleck PR, Wilson CA, Mekki Q. Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies. Journal of the American Geriatrics Society 2009 Nov;57(11):2011-9.
12. Nauck MA, Ellis GC, Fleck PR, Wilson CA, Mekki Q; Alogliptin Study 008 Group. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. International Journal of Clinical Practice 2009 Jan;63(1):46-55.
13. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). The Lancet 1998 Sep;352(9131):837-53.
14. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). The Lancet 1998 Sep;352(9131):854-65.
  

[ Содержание выпуска N 2 | Выпуски журнала | Список журналов ]